… Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading pediatric endocrinologists have long … States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on … Eton undertakes no obligation to update such statements to reflect events …

Pharmaceuticals sector stock Sigachi Industries … a leading player in pharmaceutical industry is pleased to announce … vision to deliver next-generation pharmaceutical solutions that improve therapeutic … the company announced the MoU update on Monday. The shares …

Fraser Palamara speaks Island Pharmaceuticals (ASX:ILA) CEO and managing … Dr David Foster for an update on the company’s Phase … developed in collaboration with Island Pharmaceuticals. The interviews and discussions in …

Indian stock markets are seeing a strong rally today, with both major indices surging in afternoon trade. The benchmark Sensex surged by 1.35%, reaching 80,282.23, up by 1,069.70 points. Meanwhile, the Nifty 50 also posted significant gains, climbing 1.27% …

… “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; … 17, 2007. About Innate Pharma Innate Pharma S.A. is a … X. Information about Innate Pharma shares ISIN code Ticker … undertakes no obligation to publicly update any forward-looking statements, …

Read the Full Video Transcript Zachary Klaassen: Hi, my name is Zach Klaassen, urologic oncologist at the Georgia Cancer Center. Welcome to AUA 2025. We are live on UroToday. I'm delighted to be joined by two excellent urologists, Yair Lotan from UT …

… reports, with all information updated as of April 23, … see more details here). Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks … past 5-year period. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) … focusing on high-growth pharmaceutical stocks. Overall, CPRX …

… poster titled “Preclinical and translational pharmacokinetic (PK) modeling of the self … Abstract Title: “Preclinical and translational pharmacokinetic (PK) modeling of the self … Company undertakes no obligation to update any forward-looking statement, whether …

Topline findings from the DESTINY-Breast09 trial (NCT04784715), which examined the effectiveness of fam-trastuzumab deruxtecan (T-DXd; Enhertu) plus pertuzumab (Perjeta) for first-line HER2-positive metastatic breast cancer treatment, revealed that the …

David E. Dix Retired pharmacist Jim Myers celebrated two rare events in April.  On April 10, Jim, who still plays a good round of golf, celebrated his 94th birthday. On April 16, Jim and Sally celebrated their 70th anniversary.   Jim was expecting his …